source
- FDA policy allowing compounding of unapproved peptides raises safety and development concernsThe Department of Health and Human Services recently approved the compounding of six peptide products that have not received FDA approval. This move expands the list of bulk substances that traditi…
- Karyopharm files for Chapter 11 and plans auction with Gamida Cell parent Ayrmid as lead bidderKaryopharm Therapeutics, a cash-strapped cancer drugmaker, announced a Chapter 11 filing on Monday and will conduct a court-supervised auction of the company. Ayrmid, the parent of cell-therapy co…